| Medicines policy in danger |
 |
|
|
| Drugs treated like consumer goods, and patients like
simple consumers; this may well become the norm if the proposed changes
to European medicines policy, supported by the European Commission's
Enterprises Directorate, hand in hand with the industrial lobby, are
adopted. |
|
| More
information |
|
| Download
our file free of charge |
|
French
• Click here
Medicines in Europe: campaigning goes on!
• Click here
Reorienting European Medicines Policy
Full report (354 Ko, pdf):
• Click here
In 4 parts:
• Part 1 (134 Ko,
pdf)
• Part 2 (164 Ko,
pdf)
• Part 3 (121 Ko,
pdf)
• Part 4 (146 Ko,
pdf) |
|
|
|
To clarify matters, we publish a series of documents and analyses
of European medicines policy, which applies in most Member States
(to download, see opposite).
Contents
• A call to national and European policy-makers • A free
hand • Pharmaceutical policy is now decided at the European
level • Distribution of roles within the European Union •
European pharmaceutical policy is turning its back on public health
• CPMP member's standpoint • An industry-serving pharmaceutical
policy • Dangers of the mutual recognition procedure •
Towards a medicines policy that supports basic public health needs
• Internet: Drugs agencies have a duty to inform; FDA: an example
of transparency; FDA MedWatch; EMEA: fake transparency
The overriding aim of the Forum, of which Association Mieux Prescrire
and la revue Prescrire are active members, is to inform all those
concerned by European medicines policy.
More information: Medicines
in Europe Forum
©La revue Prescrire 14 July 2002
|
|
|
|
|
